Rhonda Davis, NP
Adult Health · Millsboro, DENPI 1396055265
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Novo Nordisk at 25.8% of the total.
Across 138 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$622
- Lilly USA, LLC$305
- AstraZeneca$290
- GSK$262
- AbbVie$120
- Jazz Pharmaceuticals Inc.$104
- plus $713 from 18 others
What the payments were for
- Food & beverage$2,403100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $622 |
| Lilly USA, LLC | 16 | $305 |
| AstraZeneca | 14 | $290 |
| GSK | 14 | $262 |
| AbbVie | 6 | $120 |
| Jazz Pharmaceuticals Inc. | 5 | $104 |
| Pfizer | 5 | $88 |
| Boehringer Ingelheim | 5 | $86 |
| Exact Sciences | 3 | $77 |
| Astellas Pharma US Inc | 3 | $55 |
| Inspire Medical Systems, Inc. | 2 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Alkermes, Inc. | 2 | $37 |
| Harmony Biosciences LLC | 1 | $36 |
| Bayer | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Vertos Medical, Inc. | 1 | $21 |
| Abbott | 1 | $17 |
| Resmed Corp | 1 | $15 |
| Amgen | 1 | $15 |
| Philips North America LLC | 1 | $15 |
How this compares
$2,415 in reported general payments places this provider in the 85th percentile of 65 adult health providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 188 | $358,919 |
| JardianceEmpagliflozin | 147 | $179,046 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $52,515 |
| EliquisApixaban | 40 | $48,122 |
| TrulicityDulaglutide | 32 | $45,514 |
| TradjentaLinagliptin | 33 | $41,295 |
| FarxigaDapagliflozin Propanediol | 33 | $41,113 |
| RybelsusSemaglutide | 20 | $37,141 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $36,342 |
| MounjaroTirzepatide | 16 | $30,645 |
| XareltoRivaroxaban | 18 | $27,347 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $19,767 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $17,744 |
| JanuviaSitagliptin Phosphate | 13 | $16,075 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $15,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $622 | $396,060208 claims |
| Boehringer IngelheimJardiance, Tradjenta | $86 | $220,341180 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $262 | $108,62487 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $305 | $76,15948 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere, Breztri Aerosphere | $290 | $74,34060 claims |
| PfizerEliquis, Paxlovid | $88 | $50,82855 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $14,82611 claims |
| AbbVieSynthroid | $120 | $3,51190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 65 adult health providers in Delaware.
Other adult health in Millsboro
- Angela ToneyMillsboro$911
- Emily KellerWilmington$26K
- Mayumi Lea AnthonyNewark$16K
- Mary HighWilmington$8K
- Andrea ForsythNewark$3K
- Janice James-WebbLaurel$3K
- Leslie VerucciNewark$3K
- Adrienne WoodsWilmington$2K
- Dannette MitchellWilmington$2K
- Kathe Hefner-EricksonNewark$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.